Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis. This clinical trial will be conducted in 17 medical centers in the United States, Europe and Israel under an open IND.
Prof. Fishman, Chief Executive Officer of Can-Fite: "We are very pleased with this progress and the enthusiasm of all the investigators. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral treatment for the treatment of psoriasis."
The planned randomized, double-blind, controlled trial will compare 2 dose levels of CF101 to placebo. Approximately 300 patients will be enrolled at 17 centers, and will be treated for 24 weeks. The main outcome assessments (clinical endpoints) are Physician's Global Assessment, Body Surface Area involvement, and PASI. An interim analysis will be carried out after the 100 first patients.
Cannabis shows promise in easing endometriosis pain, new research suggests